Deferasirox, an Iron-Chelating Agent, as Salvage Therapy for Rhinocerebral Mucormycosis
نویسندگان
چکیده
منابع مشابه
Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis.
Iron availability is a critical factor in the growth of Mucorales (5). Here we report the novel use of deferasirox (Exjade; Novartis), an iron chelator recently approved by the U.S. Food and Drug Administration for the treatment of transfusionrelated iron overload (3), as salvage therapy for a patient with progressive rhinocerebral mucormycosis. A 40-year-old man presented to an outside hospita...
متن کاملPharmacogenetic Study of Deferasirox, an Iron Chelating Agent
Transfusion-associated iron overload induces systemic toxicity. Deferasirox, a convenient long acting oral agent, has recently been introduced in clinical practice with a promising efficacy. But there are some patients who experience drug-related toxicities and cannot tolerate it. To investigate effect of genetic variations on the toxicities and find optimal target population, we analyzed the g...
متن کاملRhinocerebral mucormycosis: an update.
BACKGROUND AND OBJECTIVES Mucormycoses are a group of invasive infections caused by filamentous fungi of the Mucoraceae family, with the rhinocerebral form of the disease being the most common in large case series. In the present paper we review the characteristics of the rhinocerebral form of the disease. EVIDENCE AND INFORMATION SOURCES The present review is based on the analysis of the cur...
متن کاملIsavuconazole as salvage therapy for mucormycosis
Mucormycosis carries a high mortality rate with few therapeutic options available. We describe a man with pulmonary/splenic mucormycosis complicating hypoplastic myelodysplastic syndrome on a background of chronic kidney disease, who achieved a complete response with salvage isavuconazole therapy following intolerance of consecutive courses of liposomal amphotericin and posaconazole therapy.
متن کاملSafety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis.
We sought to describe the safety profile of open-label, adjunctive deferasirox iron chelation therapy in eight patients with biopsy-proven mucormycosis. Deferasirox was administered for an average of 14 days (range, 7 to 21) at 5 to 20 mg/kg of body weight/day. The only adverse effects attributable to deferasirox were rashes in two patients. Deferasirox treatment was not associated with changes...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Antimicrobial Agents and Chemotherapy
سال: 2006
ISSN: 0066-4804,1098-6596
DOI: 10.1128/aac.01065-06